Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK523338 in Type 2 Diabetes Mellitus
NCT00256867Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of GSK523338 in type 2 diabetes mellitus (T2DM) and hypercholesterolemia, sponsored by GSK. Primary endpoint: Median Percent Change From Baseline to Week 6 in LDL-c. Started Aug 2005; status: completed.
02
Drugs
GSK523338
03
Conditions
type 2 diabetes mellitus (T2DM)hypercholesterolemia
Beyond the preview
Go deeper on NCT00256867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256867.